Home
http://www.virbac.fr/ http://www.boehringer-ingelheim.com/ http://www.novartis.com/ http://www.animalhealth.bayerhealthcare.com/
vetcontact
Vetrinär
Tiermedizin
  WELCOME  
vetcontact
Vetrinär
Tiermedizin
  Home  
  Login / Newsletter  
vetcontact
Vetrinär
Tiermedizin
  CONTACTS  
vetcontact
Vetrinär
Tiermedizin
  Classifieds  
  New Products  
  VetCompanies  
  VetSchools  
vetcontact
Vetrinär
Tiermedizin
  PROFESSION  
vetcontact
Vetrinär
Tiermedizin
  Edutainment  
  VetAgenda  
  Presentations  
  Posters  
  ESAVS  
  Specialisation  
vetcontact
Vetrinär
Tiermedizin
  INSIGHT  
vetcontact
Vetrinär
Tiermedizin
  Congress News  
  Picture Galleries  
vetcontact
Vetrinär
Tiermedizin
  PRODUCTS  
vetcontact
Vetrinär
Tiermedizin
  Bayer  
  Boehringer Ing.  
  Novartis  
  Virbac

 
  Simply book for less...  
    

Bovine    Equine    Small Animal Practice    Swine Practice    Articles    Vetjournal    
deutsch english español polski francais
Home / WELCOME / Archiv / Small Animal Practice /     
 
Promising therapy of canine haemangiosarcoma with suberoylanilide hydroxamic acid
Haemangiosarcoma is one of the most common and most aggressive tumours in dogs which is growing slowly and asymptomatical. Once the diagnosis is made, the prognosis in guarded with a median survival time from about 3 months. In this case report the dog treated with a new deacetylase (HDAC) inhibitor given orally had a survival time from more than 3 years...

A case report is presented by describing the treatment of a 12-year-old dog diagnosed with haemangiosarcoma (HSA) with suberoylanilide hydroxamic acid (SAHA), a histone deacetylase (HDAC) inhibitor.

The drug was administered orally, on a daily basis, approximately 2 weeks post-splenectomy at a dose of 3 mg kg1.

HSA is a lethal malignancy of the endothelium, which is usually disseminated by the time it is diagnosed. Median survival time, usually, is no longer than 80 days.

Following treatment with SAHA, no sign of malignant growth could be discerned by means of diagnostic abdominal ultrasound, chest X-ray or with the help of clinical symptoms, over a period of >1000 days.

The precise mechanism by which HDAC inhibitors exert their anti-cancer effects is uncertain, but evidence suggests that exposure to SAHA generates hyperacetylated chromosomal histones, which, in turn, facilitates the expression of tumour suppressor genes turned off by epigenetic mechanisms during neoplastic transformation of the endothelium.


Source: Cohen, L. A., Powers, B., Amin, S. & Desai, D. (2004): Treatment of canine haemangiosarcoma with suberoylanilide hydroxamic acid, a histone deacetylase inhibitor. In. Veterinary and Comparative Oncology 2 (4), 243-248.




Tell a friend   |   Print version   |   Send this article

SMALL ANIMAL PRACTICE

Complex atlanto-axial malformation in a rabbitmembers
A 1-year-old dwarf rabbit was presented with sub-acute progressive tetraparesis. Radiography, CT and MRI revealed compressive cervical myelopathy secondary to a complex atlanto-axial malformation including partial aplasia of the atlantal dorsal arch, dens malformation, malarticulation and lateral atlanto-occipital displacement. What should be done next?

  • Fluorescein sodium-guided resection of intracranial lesions in dogsmembers
  • Ultrasound and clinical findings in cats with urethral obstructionmembers
  • Novel technique to measure plasma lipids in diabetic dogsmembers
  • Prevalence and disease associations in feline thrombocytopeniamembers
  • Optic neuritis in dogs: an updatemembers
  • Brachycephalic airway syndrome - differences between pugs and French bulldogsmembers
  • Prognostic factors in cats with HCMmembers
  • Ureteral Papilla Implantation in Cats Undergoing Renal Transplantationmembers
  • Storage lesion in canine packed erythrocytesmembers
  • Drug-induced infiltrative lung disease with cytarabine and prednisonemembers
  • Laparoscopic-assisted Gastropexy and the Gastrointestinal Transit Time in Dogsmembers
  • Transpalpebral ultrasonographic evaluation and measurement of the optic nerve members


  • [ Home ] [ About ] [ Contact / Request ][ Disclaimer ]

    Copyright © 2001-2016 VetContact GmbH
    All rights reserved